Document:

Anavex Life Sciences Corp.: Exhibit 10.1 - Filed by newsfilecorp.com

ANAVEX LIFE SCIENCES CORP. and 
GENESIS BIOPHARMA GROUP

Page 1 of 13 

AGREEMENT FOR SERVICES 

This Agreement made and entered into on this day of August 10,
2010 by and 
between 

Anavex Life Sciences Corp. 
405 Trimmer Road 
Suite 100

Califon, NJ 07830 
USA 

(“SPONSOR“) 

and 

Genesis BioPharma Group LLC 
Admin. Office 
21 Panteli
Katelari st. 
Libra House Office Complex

2nd Floor, Office 205 
1097 Nicosia 
Cyprus

(“GBG”) 

WITNESSETH 

ANAVEX LIFE SCIENCES CORP. and 
GENESIS BIOPHARMA GROUP

Page 2 of 13 

	WHEREAS, 	The SPONSOR is a research company engaged in
      drug development. 
	  	  
	WHEREAS, 	GBG is engaged in the business of clinical
      trials management and conduct and is a full-service CRO. 
	  	  
	WHEREAS, 	The SPONSOR proposes to retain GBG to assist in
      certain clinical development activities. 
	  	  
	NOW, THEREFORE, 	in consideration of the premises and the mutual
      promises and undertakings herein contained, the parties hereto agree as
      follows: 

ANAVEX LIFE SCIENCES CORP. and 
GENESIS BIOPHARMA GROUP

Page 3 of 13 

SECTION 1: SERVICES 

		1.01: 	
      The SPONSOR hereby retains GBG to provide services to
      assist in the conduct of the project ANAVEX2-73 I/IIa clinical trials and
      overall clinical development path with resource being provided by GBG as
      outlined in Exhibit A, the outline of which is incorporated and made a
      part of this Agreement. 

	 	  	
   

		1.02: 	
      GBG hereby accepts said retainer and subject to terms and
      conditions hereinafter set forth agrees to provide the services outlined
      in Exhibit A. 

	 	  	
   

		1.03: 	
      GBG shall also provide additional services specified in
      any future Exhibit which may be agreed to between the parties in writing.
      If the SPONSOR wishes to change the scope of the services covered by this
      Agreement or wishes to obtain additional services not initially covered by
      this Agreement and/or not listed in an Exhibit, the SPONSOR shall so
      advise GBG and shall submit specifications to GBG. After receipt of the
      specifications GBG shall provide the SPONSOR with a cost estimate for
      performing the changed or additional services within a reasonable time
      frame. Each work assignment shall be governed by the terms and conditions
      of this Agreement and by such supplementary written amendments of this
      Agreement as may be, from time to time, executed between the parties. In
      the event of a conflict between the terms of this Agreement and Exhibit A,
      the terms of this Agreement shall govern. 

	 	  	
   

			
      Due to GBG’s strategic alliance with ABX-CRO advanced
      pharmaceutical services Forschungsgesellschaft m.b.H. (ABX- CRO), a
      specialized CRO in the conduct of Phase I/IIa studies, the Anavex2-73
      Phase I/IIa study conduct, as mutually agreed with SPONSOR, will be
      carried out by ABX-CRO which is located and registered in Dresden,
      Germany. GBG will have overall responsibility for the overall clinical
      development, study management, oversight, study decisions, audits,
      reports, filings, regulatory meetings, study strategies and operation of
      the Anavex2-73 Phase I/IIa clinical study. 

SECTION 2: TERM 

		2.01: 	
      This Agreement is made on the 10th day of
      August, 2010 (“Effective Date”) and shall thereafter remain in full force
      and effect until termination or expiration as provided herein.
  

ANAVEX LIFE SCIENCES CORP. and 
GENESIS BIOPHARMA GROUP

Page 4 of 13 

SECTION 3: COMPENSATION AND EXPENSES 

		3.01: 	
      In consideration of GBG’s performance of the services in
      accordance with the protocol(s) and the terms of this Agreement hereunder,
      the SPONSOR shall pay GBG the amounts specified in the Exhibit A and
      detailed budget overview provided and attached hereto or any subsequent
      Exhibit agreed to by the parties. Payment will be made on a pro rata basis
      in accordance with the payment schedule in Exhibit A upon receipt of an
      itemized monthly statement as described in Exhibit A. Should the scope of
      a project described in Exhibit A change, the fee to be paid by the SPONSOR
      pursuant to such Exhibit will be adjusted as mutually agreed upon in
      writing by the SPONSOR and GBG. 

	 	  	
       

		3.02: 	
      The SPONSOR will reimburse GBG for travel,
      telecommunications, printing and other reasonable out-of-pocket expenses
      incurred by GBG personnel at the written request of GBG as described in
      Exhibit A with a monthly cap of EUR 2,000 unless a higher amount is agreed
      to in writing the SPONSOR. 

	 	 	
       

		3.03: 	
      The fees payable under this Agreement shall not, and
      shall not be construed to, include local, state or federal or foreign
      sales, use, excise, personal property value added or other similar taxes
      or duties, and any such taxes shall be assumed and paid by the SPONSOR
      other than taxes based on the net income of GBG. 

	 	  	
       

	 	3.04: 	
      The invoices will always indicate the following
      references: 

	 	           
         Study: Anavex 2-73 
	 	           
         Protocol #: 1 
	 	or 
	 	           
         Study: Anavex 2-73 
	 	           
         Project-Code: AVX-1 
	 	  
	 	and/or others. 

ANAVEX LIFE SCIENCES CORP. and 
GENESIS BIOPHARMA GROUP

Page 5 of 13 

SECTION 4: CONFIDENTIALITY 

		4.01: 	
      With respect to any and all information indicated as
      being of a confidential nature, including, but not limited to, protocols,
      data forms, and study results acquired by GBG from the SPONSOR, as a
      result of this Agreement or from performance of the services to be
      rendered hereunder, GBG agrees that it will not use said information other
      than for the purposes of this Agreement, and it will not disclose any of
      said information to any third party except as is pursuant to the purposes
      of this Agreement. The foregoing obligation shall not apply to
      information: 

	 	1) 	
      which was known to GBG prior to its receipt from the
      SPONSOR;

	 	2) 	
      which is or lawfully becomes generally available to the
      public;

	 	3) 	
      which is lawfully acquired from third parties who have a
      right to disclose such information;

	 	4) 	
      which by mutual agreement is released from a confidential
      status.

			
      The SPONSOR acknowledges that GBG may utilize such
      material and data internally for reference, pedagogical and methodological
      purposes. 

	 	  	
   

		4.02: 	
      The terms of this Section 4, and the parties’ obligations
      hereunder, shall survive for a period of five (5) years after termination
      or expiration of this Agreement and the completion of GBG’s services
      hereunder. 

SECTION 5: TERMINATION 

		5.01: 	
      This Agreement may be terminated by either party upon
      ninety (90) days written notice by officers of either party duly
      authorized to do so. 

ANAVEX LIFE SCIENCES CORP. and 
GENESIS BIOPHARMA GROUP

Page 6 of 13 

		5.02: 	
      This Agreement may be terminated by either party upon
      default in performance of the other party, provided that any defaulting
      party shall be given not less than sixty (60) days prior written notice of
      default and at GBG’s option the opportunity to cure the default during
      such period and SPONSOR’S written agreement to the cure provisions. The
      notice of the decision to terminate must be communicated to the defaulting
      party by the other party, by registered mail with acknowledgement of
      receipt. In the event this Agreement is terminated pursuant to this
      Section 5 § 5.01, GBG shall retain such sums as may have been paid to it
      by the SPONSOR under the terms of this Agreement to compensate GBG for
      work performed in accordance with Exhibit A following receipt of final
      monitoring report and resolution of any outstanding queries, as long as
      the Agreement is terminated for reasons other GBG’s negligence,
      non-adherence to the protocol(s) or non- adherence to the protocol
      time-frame, as far as monitoring is concerned. SPONSOR shall pay GBG any
      additional amounts owed, but not yet paid, for work performed, in
      accordance with the protocol(s) up to the point of termination, unless
      agreed by both parties in writing. 

	 	  	
   

		5.03: 	
      If not sooner terminated, and excepting Sections 4, 6 and
      12, which shall survive the expiration or termination of this Agreement,
      this Agreement will expire after the completion of the work contemplated
      by Exhibit A. 

SECTION 6: INDEMNIFICATION 

		6.01: 	
      The SPONSOR agrees to defend, indemnify, and hold
      harmless GBG and its respective subsidiaries, affiliates, employees,
      directors, independent contractors and agents against and from any claims,
      proceedings, or investigations arising out of or in connection with this
      Agreement, including, without limitation, amounts paid in settlement of
      claims, proceedings, or investigations, and agrees to bear all costs and
      expenses, including, without limitation, reasonable attorneys’ fees,
      incurred in connection with the defense or settlement of any such claim,
      proceeding or investigation as such costs and expenses are incurred in
      advance of judgement, so long as GBG has strictly complied with the terms
      and conditions of work to be performed in Exhibit A Anavex2-73 protocol(s)
      and work and this Agreement, and such claim is not otherwise due to the
      fault or negligence of GBG, as far as monitoring is concerned, provided,
      

ANAVEX LIFE SCIENCES CORP. and 
GENESIS BIOPHARMA GROUP

Page 7 of 13 

			however, that the SPONSOR shall not be liable
      for any indemnification or expenses for claims, proceedings or
      investigations to the extent such claims, proceedings or investigations
      result from the negligence of GBG in performing services hereunder or
      which result from GBG’s failure to comply in all material respects with
      the terms of the Agreement. 
	 	  	 
			The SPONSOR shall be promptly notified of any
      claim being made against it or GBG and GBG shall co-operate with the
      SPONSOR in the defense of any such claim. 
	 	  	 
		6.02: 	The terms of this Section 6, and the parties’
      obligations hereunder, shall survive termination or expiration of this
      Agreement and the completion GBG’s services hereunder. 
	 	  	 
		6.03: 	In the event of delay in the performance of the
      clinical services (as described in Exhibit A) by Genesis, Genesis shall
      reimburse an indemnity, as described below, to the SPONSOR. This indemnity
      shall only be due if the delay in the performance is a consequence of
      Genesis fault and the following situations will not be considered as
      Genesis fault in the calculation of the above mentioned indemnity: 
	 	  	 
	 	  	- Any delay due to unexpected problems during
      development 
	 	  	linked to the compound specific properties.
  
	 	  	 
			- Delay in the obtention of data, compound,
      internal standard, key decision from the SPONSOR or delay of work
      performed by SPONSOR’s previously assigned vendors leading to a delay or
      postponement during, or prior, the studies. 
	 	  	 
			- Delay arising from modification in the
      development plan requested by the SPONSOR. 
	 	  	 
			If a Genesis fault can be demonstrated, the
      SPONSOR will be authorized to ask an indemnity of 0.5% of the total amount
      of clinical services per month of delay compared to the original schedule.
      In any case, this indemnity will be limited to 4 months of delay and
      therefore, Genesis indemnity will never exceed 2% of the total cost of the
      clinical services. The SPONSOR hereby agrees that he will never ask an
      indemnity exceeding 2% of the total cost of the clinical services whatever
      the final delay is. This potential indemnity will be allowed to be issued
      on the next payable invoice. 

ANAVEX LIFE SCIENCES CORP. and 
GENESIS BIOPHARMA GROUP

Page 8 of 13 

SECTION 7: PUBLICITY 

		7.01: 	
      The SPONSOR agrees that GBG may disclose that the SPONSOR
      has retained GBG for professional services subject to mutual review and
      agreement of any such publicity including, but not limited to, press
      releases, conferences and other material displayed in the public domain.
      SPONSOR shall have final editing rights to such materials as they may have
    implications on SPONSOR as a public company. 

SECTION 8: INDEPENDENT CONTRACTOR 

		8.01: 	
      GBG shall perform services under this Agreement only as
      an independent contractor, and nothing contained herein shall be construed
      to be inconsistent with that relationship or status. GBG, its
      subsidiaries, affiliates, employees and consultants shall not be
      considered employees or agents of the SPONSOR. 

	 	  	
      

			
      This Agreement shall not constitute, create, or in any
      way be interpreted as, a joint venture, partnership, or business
      organization of any kind. 

ANAVEX LIFE SCIENCES CORP. and 
GENESIS BIOPHARMA GROUP

Page 9 of 13 

SECTION 9: EMPLOYEES 

		9.01: 	
      GBG’s staff are not, nor shall they be deemed to be, at
      any time during the term of this Agreement, the employees of the SPONSOR.
      The relationship between the SPONSOR and GBG is that of independent
      contractors and in no event shall the parties be deemed to be partners,
      engaged in a joint venture, or the like. The SPONSOR agrees that neither
      it nor its subsidiaries nor other affiliated companies shall directly or
      indirectly solicit for employment, employ or otherwise retain staff of GBG
      during the term of this Agreement without the prior written consent of GBG
      officer(s) duly authorized to give such consent. 

SECTION 10: DELAYS 

		10.01: 	
      The SPONSOR acknowledges that GBG will require documents,
      drug supplies, data, records and co-operation by the SPONSOR in order to
      properly perform the services hereunder and that GBG is not responsible
      for errors, delays or other consequences arising from the failure of
      SPONSOR to provide such data, records, or co- operation. 

	 	  	
       

		10.02: 	
      The SPONSOR also acknowledges GBG will not be responsible
      for any default under this Agreement by reason of strikes, wars, fire,
      acts of God, acts in compliance with any law, rule, regulation or order of
      any governmental entity, or instrumentally thereof having jurisdiction
      over the parties or the services to be provided hereunder, or any other
      cause beyond its reasonable control. 

ANAVEX LIFE SCIENCES CORP. and 
GENESIS BIOPHARMA GROUP

Page 10 of 13 

SECTION 11: WARRANTIES 

		11.01: 	The SPONSOR warrants and represents that, to
      the best of its knowledge all information relating to this work, disclosed
      to GBG prior to signature of an Agreement on behalf of the SPONSOR was
      correct at the time of disclosure. GBG warrants and represents that it
      possesses the requisite skill, experience, and personnel to perform the
      described services, in the required timeline. 

SECTION 12: OWNERSHIP 

	 	12.01: 	
      All information, documents and raw data, excluding
      patient records, and any other third party proprietary information are
      owned by the SPONSOR. Following completion of the services outlined in
      Exhibit A, GBG will return data or other materials furnished to GBG. All
      study documentation not returned to the SPONSOR will be kept by GBG for at
      least two years after the termination of the study and GBG will inform
      sponsor of intentions related to such material at least 3 months prior to
      this 2 year period with a mutually agreed option to continue to store the
      material by SPONSOR, or otherwise archiving said material.
  

Section 13: COMMUNICATIONS AND PAYMENTS 

	 	13.01: 	
      All administrative communications in this Agreement shall
      be by courier such as FedEx, to the address mentioned in page 1. Payments
      need to be made as described in the invoices that will be sent to SPONSOR
      either in the form of a check or a direct international wire, as
      specified. GBG acknowledges that SPONSOR may withhold payment if
      deliverables substantially differ in timelines or quality from that
      represented in Exhibit A provided that such issues do not occur due to
      direct actions on the part of the SPONSOR and that GBG has already
      effected a reasonable and timely cure which has been discussed and
      suitably evidenced and agreed in writing with SPONSOR.

ANAVEX LIFE SCIENCES CORP. and 
GENESIS BIOPHARMA GROUP

Page 11 of 13 

SECTION 14: ASSIGNMENT 

	
      

      

      
	
      14.01: 
	
      Neither party shall have the right to assign this
      Agreement or any or any of the rights or obligations hereunder without the
      prior written consent of the other party. 

SECTION 15: DISCLAIMER 

		15.01: 	The SPONSOR acknowledges that the results of
      the services to be provided hereunder are inherently uncertain and that,
      accordingly, there can be no assurance, representation, or warranty by GBG
      that the product covered by this Agreement can, either during the term of
      this Agreement or thereafter, be successfully developed or, if so
      developed, will receive the required approval by the regulatory
      authorities. 
	 	  	 
		15.02: 	The SPONSOR acknowledges that GBG will provide
      professional services hereunder and not a product. THE TERMS OF THIS
      AGREEMENT EXCLUDE ALL IMPLIED WARRANTIES INCLUDING BUT NOT LIMITED TO THE
      IMPLIED WARRANTIES OF MERCHANTABLENESS AND FITNESS FOR A PARTICULAR
      PURPOSE. 
	 	  	 
		15.03: 	The SPONSOR acknowledges that the services to
      be provided by GBG hereunder are based upon information supplied by GBG
      and the SPONSOR, among other elements, and that GBG does not guarantee or
      warrant such services to any specifications, functions or other standards,
      except as outlined in the Exhibit A and that all work will be performed
      according to ICH-GCP guidelines and international health authority
      regulations. The sole remedy of the SPONSOR for any breach or default by
      GBG shall be termination of this Agreement as herein provided, and in no
      event GBG be liable for special, indirect, incidental or consequential
      damages or for any liability to a third party. 

FDA, ICH & GLOBAL Regulatory 

Regulatory Inspections. GBG,
its affiliates, employees, consultants, etc., may be inspected by the FDA or any
other authority and GBG is to ensure regulatory compliance, to document the
authenticity of recorded data, and/or to ensure quality adherence. GBG shall
promptly notify SPONSOR of any FDA or other regulatory inspection of which it
becomes aware relating to a project. SPONSOR shall have the right to be present
at any such inspections and shall have the opportunity to provide, review, and
comment on any responses that may be required. In the event GBG does not receive
prior notice of such a regulatory inspection or audit, GBG shall notify
SPONSOR as soon as practicable after said inspection or audit, and shall provide
in writing to SPONSOR, copies of all materials, correspondence, statements,
forms and records received or generated pursuant to any such inspection or
audit.

ANAVEX LIFE SCIENCES CORP. and 

  GENESIS BIOPHARMA GROUP

Page 12 of 13 

No Debarred or Disqualified Person.
GBG represents and warrants that it shall not employ, contract with, or
retain any person directly or indirectly to perform the activities described in
the Scope of Services under this Agreement if such a person: (a) is under
investigation by the FDA for debarment or is presently debarred by the FDA
pursuant to 21 U.S.C. ß 335a; or (b) has a disqualification hearing pending or
has been disqualified by the FDA pursuant to 21 CFR ß 312.70 or its successor
provisions. In addition, GBG represents and warrants that it has not engaged in
any conduct or activity which could lead to any of the above-mentioned
disqualification or debarment actions. If, during the term of this Agreement,
Vendor or any person employed or retained by it to perform the activities
described in the Scope of Services: (i) comes under investigation by the FDA for
a debarment action or disqualification; (ii) is debarred or disqualified; or
(iii) engages in any conduct or activity that could lead to any of the
above-mentioned disqualification or debarment actions, GBG shall immediately
notify SPONSOR of same and address the issue as mutually agreed upon by the
Parties. 

SECTION 16: MISCELLANEOUS 

		16.01: 	
      This Agreement constitutes the entire agreement between
      the parties on the subject matter defined in Exhibit A and supersedes all
      prior contracts, agreements, and understandings relating to the same
      subject matter between the parties. The parties intend this Agreement to
      be a complete statement of the terms of their agreement, and no change or
      modification of any of the provisions of this Agreement shall be effective
      unless it is in writing and signed by a duly authorized officer of GBG and
      the SPONSOR. 

	 	  	
   

		16.02: 	
      This Agreement between the parties shall constitute a
      basic agreement, the terms and conditions of which shall apply to each
      Exhibit agreed upon by the parties. 

	 	  	
   

		16.03: 	
      This Agreement shall be governed by and construed in
      accordance with the laws of New Jersey, USA. 

	 	  	
   

		16.04: 	
      If any one or more of the provisions of the agreement
      shall be held to be invalid, illegal or unenforceable, the validity,
      legality or enforceability of the remaining provisions of the Agreement
      shall 

ANAVEX LIFE SCIENCES CORP. and 

GENESIS BIOPHARMA GROUP 

Page 13 of 13 

not in any way be affected of impaired thereby and the invalid
  provision shall be modified to the extend required to be enforceable. 

     In Witness Whereof, the
Parties hereto have executed this Agreement on the Effective Date by proper
persons thereunto duly authorized. 

	Genesis BioPharma Group,
      LLC 	 	Anavex Life
      Sciences Corp. 
	 	 	 
	By: 		 	By: 	
	Name: Angelos M. Stergiou, MD 	 	Name: 
	Title: President & COO 	 	Title: 
	Date:	 	 	Date: 	
	 	 	 	 	 

EXHIBIT A 

TERMS OF PAYMENT AND PAYMENT SCHEDULE 

Unless otherwise indicated in writing by GBG, all prices and
charges are exclusive of Value Added Tax. All invoices are strictly net of any
taxes and payment in full of undisputed invoices must be made within 30 days of
the date of invoice. The start-up fee invoice payment must be made within 7 days
of the date of the invoice. Such payment shall be made without deduction,
deferment, set off, lien or counter-claim, of any nature. Invoicing will be made
in advance for every month of services provided. 

Exhibit A is comprised of: 

	 	a. ) 	
      power point slide proposal entitled Exhibit A which
      provides details on project work, deliverables, budget, timelines and
      assumptions

  
  

  	Anavex2-73 - Phase I/IIa Clinical Development 
	 

Table of Contents 

I. Introduction 

	Overview
  
	Experience
  
	Program Objectives
  
	Background 

II. Research Methodology for Phase I/IIa Clinical Study 

	Overview
  
	3-Part Approach
  
	Study Design
  
	Deliverables 

	III. Proposed Project Stages
	 
	IV. Budget and Timeline

2 

	Anavex2-73 - Phase I/IIa Clinical Development 
	 

Overview 

Genesis BioPharma Group is pleased to
  present Anavex Life Sciences with a proposal to clinically develop Anavex 2-73,
  targeting Alzheimer’s Disease, in Phase I/IIa in healthy volunteers and in
  patients suffering from mild cognitive impairment and/or mild-moderate
  Alzheimer’s Disease.

We will provide the following
  deliverables: 

	 	*	Audit Reports of Pre-Clinical and Manufacturing
      Facilities 
	 	 	 
		* 	Phase I/IIa Overall Clinical Study Management,
      Study Oversight, Operations, Strategy and Reports 
	 	 	 
	 	*	Regulatory Affairs Documents and Strategy 
	 	 	 
	 	*	Medical Communications and Technical Writing 
	 	 	 
	 	*	Ongoing Senior Management Availability 

3 

	Anavex2-73 - Phase I/IIa Clinical Development 
	 

Experience 

The Principals of Genesis BioPharma
  Group have broad and longstanding experience in the CNS disease area, having
  developed and published studies in Clinical Development Phases I-III, Health
  Economic studies and registry studies over the past 20 years. These studies have
  been used to seek regulatory approval, passed due-diligence, used in
  out-licensing opportunities, and to guide value messaging, pricing and formulary
  acceptance globally. 

	Within the CNS field, our experience, in addition with our Phase I unit
    in Dresden, Germany, includes amongst others: 

	 	*	Stroke 
	 	*	Multiple Sclerosis 
	 	*	Alzheimer’s Disease 
	 	*	Depression 
	 	*	Epilepsy 
	 	*	Myasthenia Gravis 
	 	*	Schizophrenia 

4 

	Anavex2-73 - Phase I/IIa Clinical Development 
	 

Genesis’ Founders 

  	> Steve Arikian, MD CEO 	 	> Angelos Stergiou, MD President
        & COO 
	 	 	 	 	   	 	 
	 	o	International Health Economist 	 	 	o	 Expertise in Clinical Development and
        Regulatory Affairs 
	 	 	 	 	 	 	 
	 	o	Columbia University School of Public Health 	 	 	o	Lecturer/Instructor at Columbia University and
        Kentucky Wesleyan College 
	 	 	 	 	 	 	
	 	o	Founder Analytica International 	 	 	o	Held positions as VP Product Development, Medical
        Director, Head of Clinical Development, Regulatory Affairs,
        Pharmacovigilance 
	 	   		 	 		
	 	o	President, Center for Health Outcomes and
        Economics, Bristol Myers Squibb 	 	 	o 	Active Member of American Academy of
        Pharmaceutical Physicians and Investigators 
	 	 	 	 	 	 	 
	 	o	Founder, APOR 	 	 		
							
	 	 	 	 	 	 	 
							

5 

	Anavex2-73 - Phase I/IIa Clinical Development 
	 

Genesis Team 

	Scientists (MD, PhD, MA/MS) 	Pre-approval Marketing 
	 	 
	Regulatory Specialists 	Financial Analysts 
	 	 
	Medical / Technical Writers 	Business Development 
	 	 
	Clinical Monitors 	Market Research 
	 	 
	Quality Assurance 	Investor Relations 
	 	 
	Data Management 	Strategic Planning 
	 	 
	Biostatistics 	Meetings Management 

6 

	Anavex2-73 - Phase I/IIa Clinical Development 
	 

Genesis’ Clinical Development Expertise 

Clinical development and regulatory affairs can be complicated
  in a changing environment with unique guidelines and stipulations. Our team will
  assure that Anavex 2-73 will be developed according to ICH-GCP guidelines and
  will expedite clinical and regulatory matters via our in-depth knowledge with
  regulators such as FDA, EMEA and other local health authorities.

7 

	Anavex2-73 - Phase I/IIa Clinical Development 
	 

Anavex 2-73 Life-Cycle Management 

The Genesis team will assure that Anavex 2-73 will be developed
  successfully, and quality- and time effectively. Our mission is to optimally
  bring Anavex 2-73 through all phases of development through demonstrated
  clinical efficacy and safety and to create, and have in place, all necessary
  reports in order for Anavex Life Sciences to position Anavex 2-73 optimally
  along its life-cycle management. We are your extended arm in all applicable
  fields and we are here to walk with you...

8 

	Anavex2-73 - Phase I/IIa Clinical Development 
	 

Clinical Development Expertise 

  	 	o	Planning of clinical trials in line with the
        product strategy 
	 	 	 
	 	o	Definition of target patients, endpoints and
        efficacy criteria 
	 	 	 
	 	o	Definition of milestones/timelines 
	 	 	 
	 	o	Definition monitoring manual 
	 	 	 
	 	o	Permanent review/supervision of trial conduct 
	 	 	 
	 	o	Continuing evaluation of trial relevance 
	 	 	 
	 	o	Statistical analysis plan 
	 	 	 
	 	o	Data management 
	 	 	 
	 	o	Discussion of data flow and queries 
	 	 	 
	 	o	Discussion of analysis 
	 	 	 
	 	o	Discussion of results 

9 

	Anavex2-73 - Phase I/IIa Clinical Development 
	 

Clinical Development Expertise (cont’d) 

	 	o	Full Biostatistical and Data Analysis Support 
	 	 	 
	 	o	Validated CRF Part 11 Compliant Data Manage-
      mentusing paper-based and eCRF  
	 	 	
	 	o	Regulatory Documentation, NDAs, INDs, eCTDs,
      Annual Reports, Investigator’s Brochures 
	 	 	
	 	o	Toxicology/Pharmacology/Efficacy Summaries,
      Tabular Data Preparation 
	 	 	
	 	o	Manuscript and Report Preparation, Literature
      Research 
	 	 	
	 	o	Promotional and Educational Materials Drafting 
	 	 	 
	 	o	Graphic Displays and Slides for Scientific
      & 
	 	 	 
	 	o	Corporate Meetings 

10 

	Anavex2-73 - Phase I/IIa Clinical Development 
	 

Clinical Development Expertise (cont’d) 

	 	o	Regular Interim Visits 
	 	 	 
	 	o	ICF review 
	 	 	 
	 	o	100% review of source documents against case
      report form 
	 	 	
	 	o	Ongoing case report form collection and
      cleaning 
	 	 	
	 	o	Provide assistance with query resolution 
	 	 	 
	 	o	Regulatory document binder review 
	 	 	 
	 	o	Drug accountability 
	 	 	 
	 	o	Continued assessment of site suitability for
      trial 
	 	 	
		o 	Site resource (training, Q&A, enrollment
      strategy) 

Low monitor turnover = continuity
  with sites 

11 

	Anavex2-73 - Phase I/IIa Clinical Development 
	 

Program Objectives: Comprehensive & Successful Phase I/IIa
  Clinical Study 

  		

	Perform quality assurance/audits at all
        facilities who have performed pre- clinical studies for Anavex 2-73 and
        handling CMC-related matters, by independent GMP/GLP certified auditor, in
        order to assure all documents and studies performed are according to
        guidelines and per regulations 
	 	 
		

	Implement and conduct a Phase I/IIa clinical
        study of Anavex 2-73 in healthy volunteers and in mild cognitively
        impaired / mild-moderate Alzheimer’s Disease patients and generate all
        applicable study reports 
	 	 
		

	Submission of documents to health regulatory
        bodies, including FDA, and conduct meetings to assure the Anavex 2-73
        clinical development path will ultimately lead to label approval 
	 	 
		

	Write scientific and technical documents and
        support in medical communications 

12 

	Anavex2-73 - Phase I/IIa Clinical Development 
	 

Alzheimer’s Disease Overview: Costs Associated with AD 

		

	Total costs of care for individuals with
      Alzheimer's disease by all payers will soar from $172 billion in 2010 to
      more than $1 trillion in 2050 with Medicare costs increasing more than 600
      %, from $88 billion today to $627 billion in 2050 
		

	It is estimated that Medicaid costs will soar
      400 %, from $34 billion to $178 billion by 2050 
		

	The average lifetime cost of care for someone
      with Alzheimer’s disease is $174,000 
		

	The yearly cost of caring for someone with
      Alzheimer's depends on the stage of the disease: 

- $18,400 for someone with mild
  symptoms 

- $30,100 for moderate symptoms 

- $36,132 for severe symptoms 

		

	Alzheimer's disease cost businesses $24.6
      billion in health care in 2002 
		

	In the US, 7 out of 10 people with Alzheimer's
      live at home where 75 % of costs are absorbed by the family. The remaining
      25 % of care costs cost an average $19,000 a year 
		

	One study estimated that in 2002 Alzheimer's
      caregivers cost businesses $36.5 billion. This includes the costs of
      absenteeism and lost productivity 
		

	The average cost of a nursing home in the US is
      $42,000 a year. However in some areas those costs can be at least $70,000 

14 

	Anavex2-73 - Phase I/IIa Clinical Development 
	 

Clinical Development: Phase I/IIa 

Study Management, Clinical 

      Operations, Report Writing and 

  Filing and Regulatory Strategu and 

  Implementation of 

  ANAVEX 2-73 

  Phase I/IIa Clinical Study Design

Phase I/IIa Study will be executed by ABX-CRO under separate
  contract with Anavex 

***

16 

	Anavex2-73 - Phase I/IIa Clinical Development 
	 

  	Timeline and Budget 

***

40Anavex Life Sciences Corp.: Exhibit 10.2 - Filed by newsfilecorp.com

Agreement between Anavex Life Sciences Corp. 
and
ABX-CRO
advanced pharmaceutical services – Forschungsgesellschaft m.b.H. 
August
10th 2010

	***Denotes certain parts that have
      not been disclosed and have been filed separately with the
      Secretary, Securities and Exchange
      Commission, and is subject to a confidential treatment request pursuant
      to Rule 24b-2 of the
      Securities Exchange Act of 1934, as amended.
  

AGREEMENT FOR SERVICES – Anavex2-73

This Agreement made and entered into on this day of August 10,
2010 by and 
between

Anavex Life Sciences Corp. 
#100, 405 Trimmer Road

Califon NJ, 07830 
USA

("SPONSOR")

and

     ABX-CRO 
advanced
pharmaceutical services 
Forschungsgesellschaft m.b.H.
Blasewitzer Str.
78-80 
D-01307 Dresden 
Germany

("ABX-CRO").

WITNESSETH

	WHEREAS, 	The SPONSOR is engaged in the business of
      clinical research and 
	  	  
	WHEREAS, 	ABX-CRO is engaged in the business of clinical
      trials management. 
	  	  
	WHEREAS, 	The SPONSOR proposes to retain ABX-CRO to
      assist in certain development activities. 
	  	  
	NOW, THEREFORE, 	in consideration of the premises and the mutual
      promises and undertakings herein contained, the parties hereto agree as
      follows: 

page 1 of 33

	Agreement between Anavex Life Sciences Corp. 
	and 
	ABX-CRO advanced pharmaceutical services –
      Forschungsgesellschaft m.b.H. 
	August 10th 2010 

SECTION 1: SERVICES

	 	1.01: 	
      The SPONSOR hereby retains ABX-CRO to provide services to
      assist in the conduct of the project Anavex2-73 with resource being
      provided by ABX-CRO outlined in an Exhibit A which is incorporated and
      made a part of this Agreement. 

	 	  	
       

	 	1.02: 	
      ABX-CRO hereby accepts said retainer and subject to terms
      and conditions hereinafter set forth agrees to provide the services
      outlined in Exhibit A. 

	 	  	
       

	 	1.03: 	
      ABX-CRO shall also provide additional services specified
      in any future Exhibit, under the auspices of Genesis BioPharma Group, LLC
      (GBG) which holds responsibility for the management and operation of the
      Anavex2-73 clinical development, which may be agreed to between the
      parties in writing. If the SPONSOR wishes to change the scope of the
      services covered by this Agreement or wishes to obtain additional services
      not initially covered by this Agreement and/or not listed in an Exhibit,
      the SPONSOR shall so advise ABX-CRO and shall submit specifications to
      ABX-CRO. After receipt of the specifications ABX-CRO shall provide the
      SPONSOR with a cost estimate for performing the changed or additional
      services. Each work assignment shall be governed by the terms and
      conditions of this Agreement and by such supplementary written amendments
      of this Agreement of this Agreement of Exhibits as may be, from time to
      time, executed between the parties and with agreement of Genesis BioPharma
      Group. In the event of a conflict between the terms of this Agreement and
      Exhibit A, the terms of this Agreement shall govern. 

      Due to ABX CRO
        strategic alliance with GBG, a vertically integrated full-service CRO, GBG
        will hold responsibility in the oversight, management and operational
        aspects of the Anavex2- 73 clinical Phase I/IIa study, as mutually agreed
    with SPONSOR, in the conduct of the Anavex2-73 Phase I/IIa clinical study. 

SECTION 2: TERM

		2.01: 	This Agreement shall be effective from the date
      of signature by both parties and shall thereafter remain in full force and
      effect until termination or expiration as provided herein.

page 2 of 33

	Agreement between Anavex Life Sciences Corp. 
	and 
	ABX-CRO advanced pharmaceutical services –
      Forschungsgesellschaft m.b.H. 
	August 10th 2010 

SECTION 3: COMPENSATION AND EXPENSES

		3.01: 	In consideration of ABX-CRO’s performance of
      the services in accordance with the protocol(s) and the terms of this
      Agreement hereunder, the SPONSOR shall pay ABX-CRO the amounts specified
      in the Exhibit A attached hereto or any subsequent Exhibit agreed to by
      the parties. Payment will be made on a pro rata basis in accordance with
      the payment schedule in Exhibit A upon receipt of an itemized monthly
      statement. Should the scope of a project described in Exhibit A change,
      the fee to be paid by the SPONSOR pursuant to such Exhibit will be
      adjusted as mutually agreed upon in writing by the SPONSOR and ABX-CRO.
  
	 	  	  
		3.02: 	The SPONSOR will reimburse ABX-CRO for travel
      and other reasonable out-of-pocket expenses, with a monthly cap of EUR
      1,000.00 unless a higher amount is agreed to in writing, incurred by
      ABX-CRO personnel at the written request of the SPONSOR unless ABX-CRO
      expressly agrees in advance to waive such reimbursement. 
	 	  	  
		3.03: 	The fees payable under this Agreement shall
      not, and shall not be construed to, include local, state or federal or
      foreign sales, use, excise, personal property value added or other similar
      taxes or duties, and any such taxes shall be assumed and paid by the
      SPONSOR other than taxes based on the net income of ABX- CRO. 
	 	  	  
	 	3.04: 	The invoices will always indicate the following
      references: 

	 	             Study:
      Anavex2-73 
	 	             Protocol
      #: Anavex2-73-01 or Anavex2-73-02 or 
	 	               
                         
                     Anavex2-73 PET
      Substudy 
	 	  
	 	  
	 	  
	 	and/or others. 

page 3 of 33

	Agreement between Anavex Life Sciences Corp. 
	and 
	ABX-CRO advanced pharmaceutical services –
      Forschungsgesellschaft m.b.H. 
	August 10th 2010 

SECTION 4: CONFIDENTIALITY

		4.01: 	
      With respect to any and all information indicated as
      being of a confidential nature, including, but not limited to, protocols,
      data forms, and study results acquired by ABX-CRO from the SPONSOR, as a
      result of this Agreement or from performance of the services to be
      rendered hereunder, ABX-CRO agrees that it will not use said information
      other than for the purposes of this Agreement, and it will not disclose
      any of said information to any third party except as is pursuant to the
      purposes of this Agreement. The foregoing obligation shall not apply to
      information: 

	 	1) 	
      which was known to ABX-CRO prior to its receipt from the
      SPONSOR;

	 	2) 	
      which is or lawfully becomes generally available to the
      public;

	 	3) 	
      which is lawfully acquired from third parties who have a
      right to disclose such information;

	 	4) 	
      which by mutual agreement is released from a confidential
      status.

			
      The SPONSOR acknowledges that ABX-CRO may utilize such
      material and data internally for reference, pedagogical and methodological
      purposes. 

	 	  	
       

		4.02: 	
      The terms of this Section 4, and the parties’ obligations
      hereunder, shall survive for a period of five (5) years after termination
      or expiration of this Agreement and the completion of ABX-CRO’s services
      hereunder. 

SECTION 5: TERMINATION

		5.01: 	
      This Agreement may be terminated by either party upon
      ninety (90) days written notice. 

	 	  	
       

		5.02: 	
      This Agreement may be terminated by either party upon
      default in performance of the other party, provided that any defaulting
      party shall be given not less than sixty (60) days prior written notice of
      default. The notice of the decision to terminate must be communicated to
      the defaulting party by the other party, by registered mail with
      acknowledgement of receipt. In the event this Agreement is terminated
      pursuant to this Section 5 § 5.01, ABX- CRO shall retain such sums as may
      have been paid to it by the SPONSOR under the terms of this Agreement to
      comensate ABX- CRO for work performed in accordance with Exhibit A
      following receipt of final monitoring report and resolution of any
      outstanding queries, as long as the Agreement is terminated for reasons
      other ABX-CRO’s negligence, non-adherence to the protocol(s) or
      non- adherence to the protocol time-frame, as far as monitoring is
      concerned. the SPONSOR shall pay ABX-CRO any additional amounts owed, but
  not yet paid, for work performed, in accordance with the protocol(s). 

page 4 of 33

	Agreement between Anavex Life Sciences Corp. 
	and 
	ABX-CRO advanced pharmaceutical services –
      Forschungsgesellschaft m.b.H. 
	August 10th 2010 

		5.03: 	
      If not sooner terminated, and excepting Sections 4, 6 and
      11, which shall survive the expiration or termination of this Agreement,
      this Agreement will expire after the completion of the work contemplated
      by Exhibit A. 

SECTION 6: INDEMNIFICATION

		6.01: 	The SPONSOR agrees to defend, indemnify, and
      hold harmless ABX-CRO and its respective subsidiaries, affiliates,
      employees, directors, independent contractors and agents against and from
      any claims, proceedings, or investigations arising out of or in connection
      with this Agreement, including, without limitation, amounts paid in
      settlement of claims, proceedings, or investigations, and agrees to bear
      all costs and expenses, including, without limitation, reasonable
      attorneys’ fees, incurred in connection with the defense or settlement of
      any such claim, proceeding or investigation as such costs and expenses are
      incurred in advance of judgement, so long as ABX-CRO has strictly complied
      with the terms and conditions of Anavex2-73 protocol(s) and this
      Agreement, and such claim is not otherwise due to the fault or negligence
      of ABX-CRO, as far as monitoring is concerned, provided, however, that the
      SPONSOR shall not be liable for any indemnification or expenses for
      claims, proceedings or investigations to the extent such claims,
      proceedings or investigations result from the negligence or wilful ABX-CRO
      in performing services hereunder or which result solely from ABX- CRO’s
      failure to comply in all material respects with the terms of the
      Agreement. 
	 	  	  
			The SPONSOR shall be promptly notified of any
      claim being made against it or ABX-CRO and ABX-CRO shall co-operate with
      the SPONSOR in the defense of any such claim. 
	 	  	  
		6.02: 	The terms of this Section 6, and the parties’
      obligations hereunder, shall survive termination or expiration of this
      Agreement and the completion ABX-CRO’s services hereunder. 
	 	  	  
		6.03: 	In the event of delay in the performance of
      the clinical services (as described in Exhibit A) by ABX-CRO, ABX-CRO
      shall reimburse an indemnity, as described below, to the SPONSOR. This
      indemnity shall only be due if the delay in the performance is a
      consequence of ABX-CRO fault and the following situations will not be
      considered as ABX-CRO fault in the calculation of the above mentioned
      indemnity: 

page 5 of 33

	Agreement between Anavex Life Sciences Corp. 
	and 
	ABX-CRO advanced pharmaceutical services –
      Forschungsgesellschaft m.b.H. 
	August 10th 2010 

- Any delay due to unexpected problems
during development linked to the compound specific properties.

- Delay arising from modification in
the development plan requested by the SPONSOR.

If an ABX-CRO fault, which is a
non-justified delay of Anavex2-73 clinical development path, can be
demonstrated, the SPONSOR will be authorized to ask an indemnity of 0.5% of the
total amount of clinical services per month of delay compared to the original
schedule, mutually agreed upon in writing by both parties. In case of same fault
of ABX-CRO exceeding 4 months of delay SPONSOR shall at its sole discretion and
without prejudice to any other of its accrued rights, be entitled, to treat the
agreement as repudiated by giving notice in writing to the ABX-CRO.

SECTION 7: PUBLICITY

		7.01: 	The SPONSOR agrees that ABX-CRO discloses that
      the SPONSOR has retained ABX-CRO for professional services. 
	 	  	  
		7.02: 	The SPONSOR consents to disclosures which the
      SPONSOR or ABX-CRO is required by law to make. 

SECTION 8: INDEPENDENT CONTRACTOR

		8.01: 	
      ABX-CRO shall perform services under this Agreement only
      as an independent contractor, and nothing contained herein shall be
      construed to be inconsistent with that relationship or status. ABX- CRO,
      its subsidiaries, affiliates, employees and consultants shall not be
      considered employees or agents of the SPONSOR. 

	 	  	
       

			
      This Agreement shall not constitute, create, or in any
      way be interpreted as, a joint venture, partnership, or business
      organization of any kind. 

page 6 of 33

	Agreement between Anavex Life Sciences Corp. 
	and 
	ABX-CRO advanced pharmaceutical services –
      Forschungsgesellschaft m.b.H. 
	August 10th 2010 

SECTION 9: EMPLOYEES

		9.01: 	
      ABX-CRO’s staff members are not, nor shall they be deemed
      to be, at any time during the term of this Agreement, the employees of the
      SPONSOR. The relationship between the SPONSOR and ABX-CRO is that of
      independent contractors and in no event shall the parties be deemed to be
      partners, engaged in a joint venture, or the like. The SPONSOR agrees that
      neither it nor its subsidiaries nor other affiliated companies shall
      directly or indirectly solicit for employment, employ or otherwise retain
      staff of ABX-CRO during the term of this Agreement without the prior
      written consent of ABX-CRO’s officer(s) duly authorized to give such
      consent. 

SECTION 10: DELAYS

		10.01: 	The SPONSOR acknowledges that ABX-CRO will
      require documents, drug supplies, data, records and co-operation by the
      SPONSOR in order to properly perform the services hereunder and that
      ABX-CRO is not responsible for errors, delays or other consequences
      arising from the failure of SPONSOR to provide such data, records, or
      co-operation. 
	 	  	  
		10.02: 	The SPONSOR also acknowledges ABX-CRO will not
      be responsible for any default under this Agreement by reason of strikes,
      wars, fire, acts of God, acts in compliance with any law, rule, regulation
      or order of any governmental entity, or instrumentally thereof having
      jurisdiction over the parties or the services to be provided hereunder, or
      any other cause beyond its reasonable control. 

SECTION 11: WARRANTIES

	 	11.01: 	
      The SPONSOR warrants and represents that, to the best of
      its knowledge all information relating to this work, disclosed to ABX- CRO
      prior to signature of an Agreement on behalf of the SPONSOR was correct at
      the time of disclosure. ABX-CRO warrants and represents that it possesses
      the requisite skill, experience, and personnel to perform the described
      services, in the required timeline. 

SECTION 12: OWNERSHIP

		12.01: 	All information, documents and raw data,
      excluding patient records, and any other third party proprietary
      information are owned by the SPONSOR. Following completion of the services
      outlined in Exhibit A, ABX-CRO will return data or other materials
      furnished to ABX-CRO. 

page 7 of 33

	Agreement between Anavex Life Sciences Corp. 
	and 
	ABX-CRO advanced pharmaceutical services –
      Forschungsgesellschaft m.b.H. 
	August 10th 2010 

SECTION 13: COMMUNICATIONS & PAYMENTS

		13.01: 	All administrative communications and payments
      provided for in this Agreement shall be by first class mail. Postage
      prepaid, addressed to the respective parties as follows:

	 	To Anavex: 	Anavex Life Sciences Corp. 
	 		 #100, 405 Trimmer
      Road  
	 	  	Califon, NJ, 07830 
	 	  	USA 
	 	  	  
	 	  	  
	 	To ABX-CRO: 	ABX-CRO advanced pharmaceutical services
    
	 	  	Forschungsgesellschaft m.b.H. 
	 	  	Blasewitzer Str. 78-80 
	 		 D-01307 Dresden,
      Germany  
	 	  	  
	 	  	  
	 	Receiving Bank: 	Dresdner Bank AG Dresden 
	 	  	BLZ: 850 800 00 
	 	  	Kto. Nr. 048 201 74 00 
	 	  	  
	 	  	BIC: DRESDEFF850 
	 	  	IBAN DE67 8508 0000 0482 0174 00 
	 	  	  
	 	  	Ref.:Anavex2-73 

SECTION 14: ASSIGNMENT

		14.01: 	Neither party shall have the right to assign
      this Agreement or any or any of the rights or obligations hereunder
      without the prior written consent of the other party. 

SECTION 15: DISCLAIMER

		15.01: 	
      The SPONSOR acknowledges that the results of the services
      to be provided hereunder are inherently uncertain and that, accordingly,
      there can be no assurance, representation, or warranty by ABX-CRO that the
      product covered by this Agreement can, either during the term of this
      Agreement or thereafter, be successfully developed or, if so developed,
      will receive the required approval by the regulatory authorities.
  

	 	  	
       

		15.02: 	
      The SPONSOR acknowledges that ABX-CRO will provide
      professional services hereunder and not a product. THE TERMS OF THIS
      AGREEMENT EXCLUDE ALL IMPLIED WARRENTIES INCLUDING BUT NOT LIMITED TO THE
      IMPLIED WARRANTIES OF MERCHANTABLENESS AND FITNESS FOR A PARTICULAR
      PURPOSE. 

page 8 of 33

	Agreement between Anavex Life Sciences Corp. 
	and 
	ABX-CRO advanced pharmaceutical services –
      Forschungsgesellschaft m.b.H. 
	August 10th 2010 

		15.03: 	
      The SPONSOR acknowledges that the services to be provided
      by ABX-CRO hereunder are based upon information supplied by ABX-CRO, the
      SPONSOR and other parties. Therefore ABX-CRO cannot guarantee or warrant
      such services to any specifications, functions or other standards, other
      than outlined in the Exhibit A. The sole remedy of the SPONSOR for any
      breach or default by ABX-CRO shall be termination of this Agreement as
      described in section 5 TERMINATION. In no event ABX-CRO will be liable for
      special, indirect, incidental or consequential damages or for any
      liability to a third party. 

FDA, ICH & GLOBAL Regulatory

Regulatory Inspections.
ABX-CRO, its affiliates, employees, consultants, etc., may be inspected by
the FDA or any other authority and ABX-CRO is to ensure regulatory compliance,
to document the authenticity of recorded data, and/or to ensure quality
adherence. ABX-CRO shall promptly notify SPONSOR of any FDA or other regulatory
inspection of which it becomes aware relating to a project. SPONSOR shall have
the right to be present at any such inspections and shall have the opportunity
to provide, review, and comment on any responses that may be required. In the
event ABX-CRO does not receive prior notice of such a regulatory inspection or
audit, ABX-CRO shall notify SPONSOR as soon as practicable after said inspection
or audit, and shall provide in writing to SPONSOR, copies of all materials,
correspondence, statements, forms and records received or generated pursuant to
any such inspection or audit.

No Debarred or Disqualified Person.
ABX-CRO represents and warrants that it shall not employ, contract with, or
retain any person directly or indirectly to perform the activities described in
the Scope of Services under this Agreement if such a person: (a) is under
investigation by the FDA for debarment or is presently debarred by the FDA
pursuant to 21 U.S.C. ß 335a; or (b) has a disqualification hearing pending or
has been disqualified by the FDA pursuant to 21 CFR ß 312.70 or its successor
provisions. In addition, GBG represents and warrants that it has not engaged in
any conduct or activity which could lead to any of the above-mentioned
disqualification or debarment actions. If, during the term of this Agreement,
Vendor or any person employed or retained by it to perform the activities
described in the Scope of Services: (i) comes under investigation by the FDA for
a debarment action or disqualification; (ii) is debarred or disqualified; or
(iii) engages in any conduct or activity that could lead to any of the
above-mentioned disqualification or debarment actions, ABX-CRO shall immediately
notify SPONSOR of same and address the issue as mutually agreed upon by the
Parties.

page 9 of 33

	Agreement between Anavex Life Sciences Corp. 
	and 
	ABX-CRO advanced pharmaceutical services –
      Forschungsgesellschaft m.b.H. 
	August 10th 2010 

SECTION 16: MISCELLANEOUS

		16.01: 	
      This Agreement constitutes the entire agreement between
      the parties on the subject matter defined in Exhibit A and supersedes all
      prior contracts, agreements, and understandings relating to the same
      subject matter between the parties. The parties intend this Agreement to
      be a complete statement of the terms of their agreement, and no change or
      modification of any of the provisions of this Agreement shall be effective
      unless it is in writing and signed by a duly authorized officer of ABX-CRO
      and the SPONSOR. 

	 	  	
      

		16.02: 	
      This Agreement between the parties shall constitute a
      basic agreement, the terms and conditions of which shall apply to each
      Exhibit agreed upon by the parties. 

	 	  	
      

		16.03: 	
      ABX-CRO shall avoid all conflicts of interest in
      performing the Services and may not solicit Anavex Life Sciences Corp. for
      further business unless it is expressly stated in writing by Genesis
      BioPharma Group for a period of five years. 

	 	  	
      

		16.04: 	
      This Agreement shall be governed by and construed in
      accordance with the laws of Germany. The competent jurisdiction in case of
      dispute between the parties will be the courts of Dresden, Germany.
  

	 	  	
      

		16.05: 	
      If any one or more of the provisions of the agreement
      shall be held to be invalid, illegal or unenforceable, the validity,
      legality or enforceability of the remaining provisions of the Agreement
      shall not in any way be affected of impaired thereby and the invalid
      provision shall be modified to the extend required to be enforceable.
    

IN WITNESS THEREOF, the following have caused this Agreement to
be executed by their respective duly authorised representatives effective as of
this day and year above written.

	Anavex Life Sciences Corp.
    	 	ABX-CRO advanced
      pharmaceutical services 
	 	 	Forschungsgesellschaft m.b.H. 
	 	 	 
	 By: 	/s/
      Harvey Lalach 	 	By: 	/s/ Andreas Kluge 
	 	 	 	 	 
	Name: Harvey Lalach 	 	Name: Andreas Kluge, MD 
	 	 	 
	Title: President 	 	Title: Managing Director 
	 	 	 
	 Date: 	August
      10, 2010 	 	Date: 	August 10, 2010 
	 	 	 	 

page 10 of 33

	Agreement between Anavex Life Sciences Corp. 
	and 
	ABX-CRO advanced pharmaceutical services –
      Forschungsgesellschaft m.b.H. 
	August 10th 2010 

EXHIBIT A

TERMS OF PAYMENT AND PAYMENT SCHEDULE

***

page 11 of 33

	Agreement between Anavex Life Sciences Corp. 
	and 
	ABX-CRO advanced pharmaceutical services –
      Forschungsgesellschaft m.b.H. 
	August 10th 2010 

EXHIBIT A

TRIAL SYNOPSIS

***

page 12 of 33

	Agreement between Anavex Life Sciences Corp. 
	and 
	ABX-CRO advanced pharmaceutical services –
      Forschungsgesellschaft m.b.H. 
	August 10th 2010 

ESTIMATES / DEFINITIONS

***

page 13 of 33

	Agreement between Anavex Life Sciences Corp. 
	and 
	ABX-CRO advanced pharmaceutical services –
      Forschungsgesellschaft m.b.H. 
	August 10th 2010 

ADDITIONAL COMMENTS

***

page 14 of 33

	Agreement between Anavex Life Sciences Corp. 
	and 
	ABX-CRO advanced pharmaceutical services –
      Forschungsgesellschaft m.b.H. 
	August 10th 2010 

Summary on Costs

***

page 15 of 33

	Agreement between Anavex Life Sciences Corp. 
	and 
	ABX-CRO advanced pharmaceutical services –
      Forschungsgesellschaft m.b.H. 
	August 10th 2010 

Payment Schedule – including PET - study

***

page 16 of 33

	Agreement between Anavex Life Sciences Corp. 
	and 
	ABX-CRO advanced pharmaceutical services –
      Forschungsgesellschaft m.b.H. 
	August 10th 2010 

Part I: Single ascending dose (SAD)

***

page 17 of 33

	Agreement between Anavex Life Sciences Corp. 
	and 
	ABX-CRO advanced pharmaceutical services –
      Forschungsgesellschaft m.b.H. 
	August 10th 2010 

Part II: Determination of oral bioavailability (BA)

***

page 18 of 33

	Agreement between Anavex Life Sciences Corp. 
	and 
	ABX-CRO advanced pharmaceutical services –
      Forschungsgesellschaft m.b.H. 
	August 10th 2010 

Part III: Multiple ascending dose

***

page 19 of 33

	Agreement between Anavex Life Sciences Corp. 
	and 
	ABX-CRO advanced pharmaceutical services –
      Forschungsgesellschaft m.b.H. 
	August 10th 2010 

	Details on Costs 
	 
	*** 

page 20 of 33

	Agreement between Anavex Life Sciences Corp. 
	and 
	ABX-CRO advanced pharmaceutical services –
      Forschungsgesellschaft m.b.H. 
	August 10th 2010 

Per Patient costs

***

page 21 of 33

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}]]